



FDA U.S. FOOD & DRUG
ADMINISTRATION

***FDASIA 705 CY 2020 Annual Report on
Inspections of Establishments***

Acronyms

API – Active Pharmaceutical Ingredient

CBER – Center for Biologics Evaluation and Research

CDER – Center for Drug Evaluation and Research

CDRH – Center for Devices and Radiological Health

CVM – Center for Veterinary Medicine

CGMP – Current Good Manufacturing Practice

CY – Calendar Year

FACTS – Field Accomplishments and Compliance Tracking System

FDA – Food and Drug Administration

FDARA – FDA Reauthorization Act of 2017

FDASIA – Food and Drug Administration Safety and Innovation Act

FDF – Finished Dosage Form

FDP – Finished Drug Product

FD&C Act – Federal Food, Drug, and Cosmetic Act

FY – Fiscal Year (October 1 – September 30)

ORA – Office of Regulatory Affairs

QS – Quality Systems

R&L – Registration and Listing

Overview

Background

On July 9, 2012, the Food and Drug Administration Safety and Innovation Act (FDASIA) (Public Law 112-144) was signed into law. FDASIA section 705 amended section 510(h) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 USC 360(h)) to require, among other things, that the Food and Drug Administration (FDA or Agency) make available on an annual basis through the Agency's website reports on inspections of establishments registered under section 510 of the FD&C Act. On August 18, 2017, the FDA Reauthorization Act of 2017 (FDARA) (Public Law 115-52) section 901(e) further amended 510(h). The content of annual reports has been modified to reflect these amendments.

Section 510 of the FD&C Act requires manufacturers, repackers, and relabelers that engage in the manufacture, preparation, propagation, compounding, or processing of human or veterinary drugs, human biological products, and devices to register their establishment(s) and submit a listing of every product in commercial distribution to FDA. This information helps FDA maintain a catalog of all human and veterinary drugs, biological products, and devices in commercial distribution in the United States. FDA uses the Official Establishment Inventory (OEI), a database maintained by the Office of Regulatory Affairs (ORA), as well as other databases to identify the subset of registered establishments that are subject to inspection.

Section 704(a) of the FD&C Act provides FDA with authority for inspections, specifically providing authority for duly appointed employees of FDA or designated officers to enter, at reasonable times, and inspect, at reasonable times and within reasonable limits and in a reasonable manner, facilities under the jurisdiction of the FD&C Act. An inspection is a careful, critical, official examination of a facility to determine its compliance with certain laws and regulations administered by FDA.

Additionally, section 510 of the FD&C Act includes requirements to establish a risk-based schedule for the inspection of drug and device establishments. The risk-based schedule must consider the known safety risks of the establishments, including the compliance history of the establishment, the inherent risk of the drug or device manufactured, prepared, propagated, compounded, or processed at the establishment, the record, history, and nature of recalls linked to the establishment, and the inspection frequency and history of the establishment.

Table of Contents

Introduction	1
Information Presented in This Report	1
Data Collection and Definitions	2
Drug and Device Establishment Registration	4
Domestic and Foreign Drug Establishments	4
Domestic and Foreign Device Establishments	4
Domestic and Foreign Drug and Device Establishment Registrations	5
Registered Drug Establishments by Type	7
Drug and Device Establishment Inspections	9
Percentage of FDA Budget Used to Fund Establishment Inspections	10
<i>Appendix A: Definitions of Key Terms</i>	<i>A-1</i>

Introduction

Information Presented in This Report

FDASIA section 705 amended section 510(h) of the FD&C Act (21 USC 360(h)) to require, among other things, that FDA make reports on inspections of registered establishments available on an annual basis through the Agency's website. A further amendment to section 510(h)(6) of the FD&C Act in section 3101(a)(2)(H) of the 21st Century Cures Act (Public Law 114-255) changed the annual reporting requirement from fiscal year (FY) to calendar year (CY), and section 901(e) of FDARA extended the publishing requirement to May 1.

Section 510(h)(6) of the FD&C Act states:

ANNUAL REPORT ON INSPECTIONS OF ESTABLISHMENTS.

Beginning in 2014, not later than May 1 of each year, the Secretary shall make available on the Internet Web site of the Food and Drug Administration a report regarding--

- (A)(i) the number of domestic and foreign establishments registered pursuant to this section in the previous calendar year; and
- (ii) the number of such domestic establishments and the number of such foreign establishments that the Secretary inspected in the previous calendar year;
- (B) with respect to establishments that manufacture, prepare, propagate, compound, or process an active ingredient of a drug or a finished drug product, the number of each such type of establishment; and
- (C) the percentage of the budget of the Food and Drug Administration used to fund the inspections described under subparagraph (A).

This report satisfies the annual reporting requirement set forth by section 510(h)(6) of the FD&C Act for CY 2020.

Data Collection and Definitions

The FDA product Centers¹ included in this Annual Report are:

- Center for Biologics Evaluation and Research (CBER)
- Center for Drug Evaluation and Research (CDER)
- Center for Veterinary Medicine (CVM)
- Center for Devices and Radiological Health (CDRH)

Data for the registration information contained in this report were generated by FDA's registration databases for CY 2020. Data for the inspection information contained in this report were generated from ORA's Field Accomplishments and Compliance Tracking System (FACTS) for CY 2020.

The data consist of the numbers of inspections conducted at drug and device establishments to evaluate compliance with current good manufacturing practice (CGMP), including both routine CGMP for drugs and Quality Systems (QS) regulations for devices, as applicable. These routine drug and device inspections will hereafter be referred to collectively as "CGMP inspection(s)." The hours of work spent preparing for, conducting, and documenting CGMP inspections, as reported by FACTS from FDA staff, were used to calculate the percentage of ORA's field medical product non-user fee funding that supported those inspections.

Due to the Coronavirus Disease 2019 (COVID-19) pandemic, FDA announced in March 2020 that it was temporarily postponing all domestic and foreign routine surveillance facility inspections. With respect to pre-approval inspections, FDA continued to use other tools and approaches where possible, including requesting existing inspection reports from other trusted foreign regulatory partners through mutual recognition and confidentiality agreements, requesting information from applicants, and requesting records and other information directly from facilities and other inspected entities. FDA also continued to conduct inspections deemed to be mission-critical during this time.² Beginning the week of July 20, 2020, FDA began to work toward resuming prioritized domestic inspections, as described in the FDA statement "Coronavirus (COVID-19) Update: FDA prepares for resumption of domestic inspections with new risk assessment system" issued on July 10, 2020.³ As explained in this statement, FDA developed a COVID-19 Advisory Rating system that continues to assist the Agency in determining where it is safest to conduct prioritized domestic inspections, including pre-approval and surveillance inspections.

Tables 1 and 3 show data only about drug establishments; Table 2 shows data only about device establishments; Tables 4 and 5 show data about both drug and device establishments.

¹ More information on the FDA product Centers and ORA can be found at: www.fda.gov/aboutFDA/Centersoffices/default.htm.

² See guidance for industry, "Manufacturing, Supply Chain, and Drug and Biological Product Inspections During COVID-19 Public Health Emergency Questions and Answers," for a discussion of the types of inspections that would be deemed "mission-critical." The guidance is available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents>.

³ See www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-prepares-resumption-domestic-inspections-new-risk-assessment-system.

The numbers reported in Table 4 are only for CGMP inspections. However, registered drug and device establishments are subject to other types of inspections, such as product-specific inspections, pre-approval inspections, and for-cause inspections. Therefore, while Tables 1 and 2 show registered drug and device establishments respectively, Table 4 shows the specific subset of the CGMP domestic and foreign inspections FDA may conduct at those establishments. Table 5 shows the percentage of the ORA field medical product non-user fee funding involved in conducting domestic and foreign drug and device establishment CGMP inspections.

The financial data are reported on a fiscal year basis; and all other data provided in this report is based on calendar year ending December 31, 2020.

Definitions of key terms used throughout this report can be found in Appendix A.

Drug and Device Establishment Registration

Domestic and Foreign Drug Establishments

In CY 2019, a total of 13,625 drug establishments registered with FDA pursuant to section 510 of the FD&C Act. As of December 31, 2020, 10,068 domestic and 9,354 foreign drug establishments registered with FDA, bringing the total number of CY 2020 registered drug establishments to 19,422. The following tables provide data about domestic and foreign registered drug establishments.

Table 1: Number of Domestic and Foreign Registered Drug Establishments

Location	CY 17	CY 18	CY 19	CY 20
Domestic	9,092	9,687	9,464	10,068
Foreign	4,103	4,241	4,161	9,354
Total	13,195	13,928	13,625	19,422

Domestic and Foreign Device Establishments

In CY 2020, a total of 42,278 medical device establishments registered with FDA. The following table provides data about domestic and foreign registered device establishments.⁴

Table 2: Number of Domestic and Foreign Registered Device Establishments

Location	CY 17	CY 18	CY 19	CY 20
Domestic	13,596	13,707	13,857	16,190
Foreign	12,755	13,143	14,287	26,088
Total	26,351	26,850	28,144	42,278

⁴ For the purposes of this report, CDRH registration counts reflect the total number of firms that registered during the year, including those that deactivated their registrations later in the year. The breakdown by establishment type included in the Medical Device User Fee Act (MDUFA) quarterly report, available at www.fda.gov/media/135471/download, covers only those that were still active at the end of each quarter or fiscal year.

Domestic and Foreign Drug and Device Establishment Registrations

The following two charts show the number of domestic and foreign drug and device establishments registered in CY 2017, CY 2018, CY 2019, and CY 2020:

Chart 1: Number of Domestic and Foreign Registered Drug Establishments





Chart 2: Number of Domestic and Foreign Registered Device Establishments



We believe that the increase in device establishment registrations in CY 2020 was due to the registration of new establishments that engaged in the manufacture, preparation, propagation, compounding, or processing of devices to accommodate the high demand for personal protective equipment (PPE) and other medical devices during the COVID-19 emergency. Additionally, FDA registration data illustrates a steady increase of new registrations, starting in the spring and growing throughout the calendar year.

Registered Drug Establishments by Type

In CY 2020, a total of 9,249 establishments registered as Finished Drug Product (FDP) establishments and 1,837 establishments registered as Active Pharmaceutical Ingredient (API) establishments.

The table below provides a breakdown of the number of establishments that registered as FDP and API establishments in CYs 2017, 2018, 2019, and 2020.

For the purposes of this report, if an establishment manufactures, prepares, propagates, compounds, or processes both FDP and API, it is counted as an FDP establishment. API establishments are involved solely in the production of an API. The “Other” category includes but is not limited to establishments that manufacture, prepare, propagate, compound, or process medical gases or medicated feed; and establishments that register through the registration system maintained by CBER. This report excludes drug establishments registered as section 503B compounders (or Outsourcing Facilities).

Table 3: Types of Registered Drug Establishments

	FDP	API	Other	Total
CY 2017	4,482	1,590	7,123	13,195
CY 2018	4,183	1,701	8,044	13,928
CY 2019	3,864	1,709	8,052	13,625
CY 2020	9,249	1,837	8,336	19,422


After the declaration of the COVID-19 public health emergency in January 2020, consumers and health care personnel were experiencing difficulties accessing alcohol-based hand sanitizers. The increase in demand led to a surge of non-traditional manufacturers like alcohol distilleries, oil refiners, and industrial chemical establishments beginning to produce hand sanitizer products. To help address the situation, in early March 2020, CDER published a [guidance⁵](#) entitled “Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)” explaining that FDA does not intend to take enforcement action with respect to certain violations of the FD&C Act regarding the preparation of hand sanitizer products provided that the circumstances described in the guidance are present.

The data sources for the reported FDP and API establishments are the registration databases maintained by CDER and CVM, the only drug registration data sources that include such information. Establishments that produce certain types of biological products register through the registration system maintained by CDER.

⁵ Available at www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-temporary-policy-preparation-certain-alcohol-based-hand-sanitizer-products-during.

The following chart shows registered drug establishments by type for CYs 2017, 2018, 2019, and 2020.

Chart 3: Number of Registered Drug Establishments by Type



Drug and Device Establishment Inspections

FDA completed a total of 1,083 CGMP inspections of registered drug and device establishments in CY 2020.⁶ The following tables show domestic and foreign inspection data for drugs and devices for CYs 2017, 2018, 2019, and 2020.

Table 4: CGMP Inspections of Registered Domestic and Foreign Drug and Device Establishments

Location	CY 2017	CY 2018	CY 2019	CY 2020
Domestic	3,479	3,297	3,139	879
Foreign	1,457	1,321	1,200	204
Total	4,936	4,618	4,339	1,083

These inspection numbers include CGMP inspections for drugs and QS inspections for Class II and Class III devices. The number of inspections of animal drug establishments includes CGMP inspections of some non-registered facilities and inspections that are conducted by states under a contract with FDA. However, the number of CGMP inspections does not include other types of inspections that FDA conducts (such as product-specific or pre-approval inspections of drug establishments and inspections of Class I device establishments).

⁶ CY 2020 inspection numbers reflect the impact of the COVID-19 global pandemic and resulting travel and other restrictions that limited conducting inspections to those determined to be mission-critical, starting in March 2020.

Percentage of FDA Budget Used to Fund Establishment Inspections

FDA is able to provide the percentage of ORA's field medical product program resources involved in conducting CGMP inspections of domestic and foreign drug and device establishment by fiscal year.⁷ In addition to CGMP inspections, ORA conducts many other types of establishment inspections such as product-specific, pre-approval, and pre-license inspections, Good Laboratory Practice inspections, bioequivalence inspections, and inspections of clinical investigators, Institutional Review Boards, and application sponsors.

As the risks associated with the pandemic challenged our ability to conduct inspections, FDA continued to use every available tool to ensure that our oversight responsibilities were met efficiently and in a timely manner. FDA has made full use of our authority under section 704(a)(4) of the FD&C Act to request and remotely review records from facilities that manufacture drugs and biologics in advance or in lieu of an inspection, as well as other approaches to evaluating facilities remotely.

Additionally, the Agency has developed guidance documents for industry that address key topics for consideration.⁸ Our fundamental goal is to maximize our resources in every way possible to achieve the optimal public health outcomes. We remain committed to our mission to promote and protect the health of the American public and ensure access to safe and high-quality products.

The ORA total non-user fee funding for FY 2020 was \$1,118,165,000. Approximately \$305,393,000 of this amount was devoted to field medical product programs (hereafter referred to as "field medical product non-user fee funding"), while the remaining \$812,772,000 was devoted to field programs for other products (e.g., foods). The total field medical product non-user fee funding is calculated by adding the non-user fee appropriated funding for human drugs, biologics, animal drugs, and devices and radiological health field programs.

⁷ While section 510(h)(6)(C) of the FD&C Act calls for the percentage of the budget associated with the "inspections described under subparagraph (A)," i.e., those inspections conducted in CY 2020 as reported on p. 3 above, FDA believes that continuing to report the budget by FY as in past years gives a more accurate picture of its drug and device inspection resource use. For example, the underlying data points that are used to calculate the total non-user fee funding reported in this report, such as the Prescription Drug User Fee Act (PDUFA) inflation rate and fully loaded full-time equivalent (FTE) cost, are based on the FY.

⁸ For example, on April 14, 2021, we issued a final guidance, "Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities During the COVID-19 Public Health Emergency Guidance for Industry," available at www.fda.gov/regulatory-information/search-fda-guidance-documents/remote-interactive-evaluations-drug-manufacturing-and-bioresearch-monitoring-facilities-during-covid.

ORA Non User Fee Funding	FY 20
Medical Product Programs	\$305,393,000
Field Programs for Other Products	\$812,772,000
Total	\$1,118,165,000

The field “Medical Product non-user Fee Funding” includes all field activities that support FDA’s biologics, human drugs, animal drugs, and medical device programs by assessing compliance with applicable laws and regulations. These activities include inspecting establishments, conducting sample analyses, examining products offered for entry into the United States, and certain emergency preparedness and response activities for FDA-regulated medical products. Of the \$305,393,000 field medical product non-user fee funding, approximately \$37,611,000 was used for domestic drug and device establishment CGMP inspections, and approximately \$13,503,000 was used for foreign drug and device establishment CGMP inspections during FY 2020.

Medical Product non-user Fee Funding	FY 20*
Domestic drug and device establishment CGMP inspections	\$37,611,000
Foreign drug and device establishment CGMP inspections	\$13,503,000
Total	\$305,393,000

* In accordance with national guidelines due to the COVID-19 pandemic restrictions, ORA has had to scale back foreign and domestic inspection work and target its resources on the highest- risk facilities and industries. As a result, the percentage of field medical product non-user fee funding used to fund domestic and foreign drug and device establishment CGMP inspections was significantly lower in FY 2020.

The numbers reported above are derived from the total FDA investigator and laboratory analyst hours reported by FACTS for the field medical product inspections. The estimated cost of these hours was then used to calculate the percentage of the field medical product non-user fee funding used for both domestic and foreign drug and device establishment CGMP inspections. These percentages are based solely on the estimated cost for FY 2020 of ORA’s field program resources. Field program resources include operational costs, such as onsite inspections of establishments and support personnel. These percentages do not include other resources related to the reported inspections, such as resources utilized in resulting compliance or enforcement activities involving inspected establishments.

In FY 2020 the percentage of the field medical product non-user fee funding used to fund domestic drug and device establishment CGMP inspections was approximately 12.29 percent.⁹

The percentage of the field medical product non-user fee funding used to fund foreign drug and device establishment CGMP inspections was approximately 4.41 percent.

⁹ This percentage does not include inspections of animal drug establishments conducted by the states under a contract with FDA.

Table 5 below shows the percentage of the ORA field medical product non-user fee funding involved in conducting domestic and foreign drug and device establishment CGMP inspections in FYs 2017 through 2020.

In addition to the total non-user fee funding described above, user fee funds are made available to support ORA’s field medical product program under the Prescription Drug User Fee Amendments of 2017 (PDUFA), the Generic Drug User Fee Amendments of 2017 (GDUFA), the Medical Device User Fee Amendments of 2017 (MDUFA), the Animal Drug User Fee Amendments of 2018 (ADUFA), Animal Generic Drug User Fee Amendments of 2018 (AGDUFA), the Biosimilar User Fee Amendments of 2017 (BsUFA), and the Drug Quality and Security Act (DQSA). These numbers were not included in the calculations for this report.

Table 5: Percentage of ORA Field Medical Product Non-User Fee Funding Used to Fund Drug and Device Establishment CGMP Inspections

Location	FY 17	FY 18	FY 19	FY 20
Domestic	45%	44%	44%	12%
Foreign	31%	29%	29%	4%
Total	76%	73%	73%	16%

Appendix A: Definitions of Key Terms

Active Pharmaceutical Ingredient means any substance that is intended for incorporation into a finished drug product and is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. Active pharmaceutical ingredient does not include intermediates used in the synthesis of the substance.

"Device" - means an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component, part, or accessory, which is (1) recognized in the official National Formulary, or the United States Pharmacopeia, or any supplement to them, (2) intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or (3) intended to affect the structure or any function of the body of man or other animals, and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of its primary intended purposes. The term 'device' does not include software functions excluded pursuant to section 520(o) of the FD&C Act. Section 201(h) of the FD&C Act (21 USC 321(h)).

"Drug" - means (A) articles recognized in the official United States Pharmacopoeia, official Homoeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; and (B) articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals; and (C) articles (other than food) intended to affect the structure or any function of the body of man or other animals; and (D) articles intended for use as a component of any articles specified in clause (A), (B), or (C). (Section 201(g) of the FD&C Act (21 USC 321(g))).

Finished Drug Product - means a finished dosage form (e.g., tablet, capsule, or solution) that contains at least one active pharmaceutical ingredient, generally, but not necessarily, in association with other ingredients in finished package form suitable for distribution to pharmacies, hospitals, or other sellers or dispensers of the drug product to patients or consumers.



FDA U.S. FOOD & DRUG
ADMINISTRATION

**Department of Health and Human Services
Food and Drug Administration**

This report was prepared by FDA's Office of Planning in collaboration with the Center for Biologics Evaluation and Research (CBER), the Center for Drug Evaluation and Research (CDER), Center for Devices and Radiological Health (CDRH), Center for Veterinary Medicine (CVM), and the Office of Regulatory Affairs (ORA). For information on obtaining additional copies contact:

Office of Planning
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, Maryland 20993-0002
Phone: 301-796-4850

This report is available on the FDA Home Page at www.fda.gov.